myelofibrosis

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  

myelofibrosis
Feb 19, 2025, 09:01 | Blog
Naveen Pemmaraju: Honored to be invited at the 14th Joyce Niblak Memorial MPN Patient Conference
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the…
Jan 20, 2025, 17:28 | Blog
Akriti Jain: How I Treat Anemia in Myelofibrosis
Akriti Jain, Leukemia and Myeloid Disorders Physician at Cleveland Clinic, posted the following on X:…
Jan 14, 2025, 18:49 | Science
Naveen Pemmaraju: Addition of navitoclax to ruxolitinib for patients with myelofibrosis
Naveen Pemmaraju, Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a…
Jan 14, 2025, 12:50 | Science
Clearance of Driver Mutations after Transplantation for Myelofibrosis by Nico Gagelmann et al.
Eddie Cliff, Haematology Registrar at Peter MacCallum Cancer Centre, shared a post on X about a…
Jan 13, 2025, 09:56 | Science
Naveen Pemmaraju: Navitoclax BCLxL Inhibition in patients with myelofibrosis
Naveen Pemmaraju, Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a…
Jan 13, 2025, 09:24 | Science
Nico Gagelmann: Clearance of driver mutations after transplantation for myelofibrosis
Nico Gagelmann, Co-founder and Co-chair of the European Society for Blood and Marrow Transplantation (EBMT)…
Jan 11, 2025, 15:00 | Insight
Nico Gagelmann: The power of transplantation to reverse-engineer ‘chronic’ disease
Nico Gagelmann, Co-founder and Co-chair the European Society for Blood and Marrow Transplantation (EBMT) Trainee…
Dec 8, 2024, 06:21 | Insight
Understanding and treating myelofibrosis
Nico Gagelmann shared a post on X: "Understanding and treating myelofibrosis A short thread on…
Dec 4, 2024, 18:03 | Insight
Teresa Bitetti: Addressing treatment gaps across a range of cancers with Keros Therapeutics
Teresa Bitetti, President of Global Oncology at Takeda, shared a post LinkedIn: “With patient needs…
Oct 14, 2024, 15:52 | Blog
Ashwin Kishtagari: Naveen Pemmaraju explores the potential of novel JAK inhibitors in myelofibrosis
Ashwin Kishtagari, Assistant Professor at Vanderbilt-Ingram Cancer Center, shared on X: '' Naveen Pemmaraju explores…
Oct 6, 2024, 12:48 | Insight
Yu-Hung Wang: Our latest myelofibrosis research
Yu-Hung Wang, PhD student at The University of Manchester, shared a post on X about…
Sep 27, 2024, 10:06 | Dialogues
ASCO24 Updates: Dr. Sankalp Arora on Azacitidine - Ruxolitinib Combination for High-Risk Myelofibrosis
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Sep 25, 2024, 14:16 | Opinion
Megan-Claire Chase: I am ALWAYS educating myself on my mother’s rare blood cancer
Megan-Claire Chase posted the following on LinkedIn: “I spent Saturday at The Leukemia & Lymphoma…
Sep 24, 2024, 16:24 | Insight
Combination vs monotherapy for management of myelofibrosis
Talha Badar posted on X: "Interesting debate on combination vs monotherapy for management of myelofibrosis. Efficacy…
Sep 2, 2024, 16:02 | Blog
Naveen Pemmaraju: Fantastic venue with mix of pre-clinical and clinical presentations focused on novel pathways in heme malignancies
Naveen Pemmaraju shared on LinkedIn: “I recently gave an invited faculty talk at ISEH -…
Aug 23, 2024, 14:01 | Insight
J.J. Kiladjian: First European Use of Anti-Mutant CALR Bispecific Antibody for Myelofibrosis
J.J. Kiladjian, Professor of Clinical Pharmacology at Paris Diderot University, shared on X: "Today at…
Aug 19, 2024, 10:38 | Insight
Hagop Kantarjian: All you need to know about the latest JAK inhibitor to be approved for myelofibrosis
Hagop Kantarjian shared a post on X about a recent paper by Prithviraj Bose published…
Aug 12, 2024, 13:49 | Drugs
SENTRY study - investigating the safety and efficacy of the combination of selinexor plus ruxolitinib in myelofibrosis
Icahn School of Medicine at Mount Sinai shared on X: "The SENTRY study, led by…
Aug 5, 2024, 14:06 | Insight
Nico Gagelmann: Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older
Nico Gagelmann, Chair of CAR-T for plasma cell disorder committee and Chair Trainee Committee at The…
Aug 1, 2024, 14:55 | Blog
Naveen Pemmaraju: Honored to be a featured MPN faculty speaker for upcoming Research Town Hall on Myelofibrosis
Naveen Pemmaraju shared a post on LinkedIn: "Honored to be a featured MPN faculty speaker…
Aug 1, 2024, 03:00 | Insight
IDH2 mutation accelerates TPO-induced myelofibrosis
Yu-Hung Wang, PhD student at The University of Manchester, shared a post on X about…
Jul 31, 2024, 00:07 | Insight
Important dataset that informs current practice for MF
Prithviraj Bose, Professor of Leukemia at MD Anderson Cancer Centre, shared on X: "Important dataset that…
Jul 2, 2024, 08:18 | Blog
Naveen Pemmaraju: Navitoclax and Ruxolitinib in Patients With Untreated Myelofibrosis
Naveen Pemmaraju shared a post on LinkedIn: “A huge shout out to all of you…
Jun 18, 2024, 23:12 | Insight
Koschmieder: Current standard and novel targets for myelofibrosis
Talha Badar shared on X:        . "Koschmieder: current standard and novel targets…
Jun 15, 2024, 16:54 | Blog
Our ongoing series “Current Thinking in Myelofibrosis” received The Spring 2024 Digital Health Award - PeerDirect
Ruben Mesa shared the following post by PeerDirect on LinkedIn: “So honored to have taken part…
Jun 15, 2024, 12:41 | Blog
Naveen Pemmaraju: With MPN Guru and dear friend Prof Ruben Mesa at EHA2024
Naveen Pemmaraju recently shared a post on X: “Wonderful to be here at EHA2024 with MPN…
Jun 11, 2024, 14:59 | Insight
Timos Papagatsias: EHA24 is expected to be one of the most exciting EHA conferences to-date!
Timos Papagatsias, CEO of LucidQuest shared a post on LinkedIn: “EHA24 is fast approaching and…
May 25, 2024, 09:12 | Insight
Sankalp Arora: Excited to be presenting longterm follow up results of AZA + RUX in patients with myelofibrosis at ASCO24
Sankalp Arora, Heme/Onc fellow at MD Anderson Cancer Center, shared on X/Twitter: "The ASCO24 countdown begins!…
May 22, 2024, 03:21 | Insight
Rahul Gosain: HemeSeries, with Naveen Pemmaraju we discuss treatment options and current landscape of Myelofibrosis
Rahul Gosain, Director of Regional Infusion Services at Wilmot Cancer Institute, shared on LinkedIn: “HemeSeries: with Naveen…
May 20, 2024, 05:51 | Blog
Blood Cancers Today - Out now! The first MPN roundtable from HOPLive24.
Blood Cancers Today shared a post on LinkedIn: "Out now! The first MPN roundtable from HOPLive24.…
May 8, 2024, 01:20 | Drugs
Talha Badar: Myelofibrosis after failure of Ruxolitinib
Talha Badar, Assistant Professor at Mayo Clinic Comprehensive Cancer Center shared a thread on Twitter/X:…
Apr 26, 2024, 08:09 | Blog
Hagop Kantarjian: The results of the first clinical trial to explore activin receptor ligand traps of drugs in MF
Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X: ''Activin receptor…
Apr 13, 2024, 11:41 | Insight
Nico Gagelmann: Methodological challenges in the development of endpoints for myelofibrosis clinical trials
Nico Gagelmann, Chair of CAR-T for plasma cell disorder committee and Chair Trainee Committee at…
Mar 31, 2024, 23:26 | Blog
Naveen Pemmaraju: Delighted to share my The Bloodline Podcast for Patients & Caregivers
Naveen Pemmaraju recently shared a post on LinkedIn: “Delighted to share my The Bloodline Podcast for…
Feb 12, 2024, 16:02 | Blog
Jean-Paul Kress: MorphoSys announced that it has entered into a business combination agreement to be acquired by Novartis
Jean-Paul Kress, CEO of MorphoSys, shared on LinkedIn: "Last week, MorphoSys announced that it has…
Jan 29, 2024, 14:55 | Blog
David Almaguer: Don't forget that HSCT cures patients
David Almaguer, Professor of Hematology at Autonomous University of Nuevo León (UANL), shared on X/Twitter:…
Dec 31, 2023, 12:04 | Blog
Key updates in the treatment and management of myeloproliferative neoplasms - Video Journal of Hematology and Hematological Oncology
Quoting Video Journal of Hematology and Hematological Oncology on LinkedIn: "NEW MPN Session from ASH23.…
Dec 1, 2023, 07:34 | Drugs
David Steensma: Fascinating to see combination trials of ruxolitinib+ reading out in myelofibrosis
David Steensma, Chief Medical Officer of Ajax Therapeutics, posted on X/Twitter: “After so many years…
Nov 22, 2023, 02:47 | Blog
Lucia Masarova: Let's tackle the inflammation in myelofibrosis! Era of combinational therapies is here
Lucia Masarova, Assistant Professor of the Department of Leukemia at MD Anderson Cancer Center, shared…
Sep 16, 2023, 18:02 | Drugs
Ruben A. Mesa: Deeply excited by the Food and Drug Administration approval of Momelotinib for patients with myelofibrosis with anemia.
Quoting Ruben A. Mesa, the President of Atrium Health Levine Cancer, on X/Twitter: "Deeply excited…
Sep 8, 2023, 16:13 | Societies
Naveen Pemmaraju: Delighted to be recognized by the Society of Hematologic Oncology for the Honorable Distinction Award
Naveen Pemmaraju, Leukemia Professor at the MD Anderson Cancer Center, shared on his Twitter account:…
Jul 3, 2023, 18:40 | Blog
We propose molecular monitoring + donor lymphocyte infusion as standard of care for relapsed myelofibrosis after BMT
In a post by Nico Gagelmann on Twitter, it says, "We propose molecular monitoring +…
Jun 17, 2023, 15:37 | Drugs
Super results in transfusion-dependent patients on ruxolitinib - Francesco Passamonti
It was a great honor to present at EHA 2023 on behalf of all investigators…
All: 43 Posts: 1 - 100
Special Coverage